All patients received at least two rounds of nocturnal penile tumescence and rigidity (NPTR) testing and/or audiovisual sexual stimulation (AVSS), then completed the International Index of Erectile Function-5 (IIEF-5) questionnaire, followed by oral 5 mg tadalafil daily for 4 weeks. After a 4-week washout period, all respondents underwent an the IIEF-5 questionnaire again. ED patients were then categorized into tadalafil responders and tadalafil non-responders, who were then further divided into cured patients and uncured patients.
When predicting tadalafil responders, the area under the curve (AUC) of NPTR was superior to that of AVSS (0.68~0.84 VS 0.69~0.73), and the predicted optimal cut-off values were DOEE60≥17.75 min in NPTR, compared to other parameters regardless of AVSS or NPTR (P<0.05). When predicting which patients would be cured, the AUC of AVSS was superior to NPTR parameters (0.77~0.81 vs 0.61~0.76), and the determined best diagnostic cut-off values were DOEE≥4.125min in AVSS, compared to other parameters regardless of AVSS or NPTR (P < 0.05).
Rigiscan was able to predict the efficacy of daily tadalafil accurately and efficiently. Its diagnostic value was at maximum when DOEE60 ≥17.75 min of NPTR in tadalafil responders and DOEE ≥ 4.125 min of AVSS in cured patients.
所有患者接受至少两轮夜间阴茎肿胀和僵硬(NPTR)测试和/或视听性刺激(AVSS)。然后完成了国际勃起功能指数-5(IIEF-5)问卷,随后口服5mg他达拉非,每日4周。经过4周的冲洗期,所有受访者再次接受了IIEF-5问卷.然后将ED患者分为他达拉非应答者和他达拉非非应答者,然后进一步分为治愈患者和未治愈患者。
在预测他达拉非反应者时,NPTR的曲线下面积(AUC)优于AVSS(0.68〜0.84VS0.69〜0.73),在NPTR中,预测的最佳截止值为DOEE60≥17.75min,与其他参数相比,无论AVSS或NPTR(P<0.05)。当预测哪些患者会被治愈时,AVSS的AUC优于NPTR参数(0.77〜0.81vs0.61〜0.76),在AVSS中确定的最佳诊断临界值为DOEE≥4.125min,与其他参数相比,无论AVSS或NPTR(P<0.05)。
Rigiscan能够准确有效地预测每日他达拉非的疗效。当他达拉非应答者的DOEE60≥17.75minNPTR和治愈患者的DOEE≥4.125minAVSS时,其诊断价值最大。